Remote Ischemic Preconditioning To Reduce Contrast-Induced Nephropathy: A Randomized Controlled Trial.

BACKGROUND: Despite the increasing use of pre- and post-hydration protocols and low osmolar instead of high osmolar iodine containing contrast media, the incidence of contrast induced nephropathy (CIN) is still significant. There is evidence that contrast media cause ischemia reperfusion injury of the renal medulla. Remote ischemic preconditioning (RIPC) is a non-invasive, safe, and low cost method to reduce ischemia reperfusion injury. The aim of this study is to investigate whether RIPC, as an adjunct to standard preventive measures, reduces contrast induced acute kidney injury in patients at risk of CIN. METHODS: The RIPCIN study is a multicenter, single blinded, randomized controlled trial in which 76 patients at risk of CIN received standard hydration combined with RIPC or hydration with sham preconditioning. RIPC was applied by four cycles of 5 min ischemia and 5 min reperfusion of the forearm. The primary outcome measure was the change in serum creatinine from baseline to 48 to 72 hours after contrast administration. RESULTS: With regard to the primary endpoint, no significant effect of RIPC was found. CIN occurred in four patients (2 sham and 2 RIPC). A pre-defined subgroup analysis of patients with a Mehran risk score ≥11, showed a significantly reduced change in serum creatinine from baseline to 48 to 72 hours in patients allocated to the RIPC group (Δ creatinine -3.3 ± 9.8 µmol/L) compared with the sham group (Δ creatinine +17.8 ± 20.1 µmol/L). CONCLUSION: RIPC, as an adjunct to standard preventive measures, does not improve serum creatinine levels after contrast administration in patients at risk of CIN according to the Dutch guideline. However, the present data indicate that RIPC might have beneficial effects in patients at a high or very high risk of CIN (Mehran score ≥ 11). The RIPCIN study is registered at: http://www.controlled-trials.com/ISRCTN76496973.

Usefulness and applicability of femorofemoral crossover bypass grafting.

We examined the usefulness of femorofemoral crossover bypass grafting (FFC) and factors influencing its outcome by retrospectively analyzing all FFCs performed in our hospital over a 5-year period, focusing on both patency rates and clinical efficacy. For 95 patients Kaplan-Meier patency rates were calculated (follow-up 40.4 +/- 3.0 months). Clinical outcome was defined according to Rutherford's standardized categories. The influence of cardiovascular risk factors and technical characteristics on outcome was determined. Clinical status of the limb remained improved in 89%. One- and 5-year primary, primary assisted, and secondary patency rates were 88.2% and 57.3%, 90.6% and 62.4%, and 92.6% and 68.1%, respectively. Clinical outcome of the limb was better in patients with <50% stenosis in the femoral arteries preoperatively (p = 0.033). No predictors for patency rates were identified. FFCs are effective in the medium long term for patients in all age categories independently of cardiovascular risk factors. The best predictor of clinical outcome is the preoperative degree of stenosis, with a better outcome for patients affected by <50% stenosis. Success of FFC cannot be reliably measured by graft patency alone but should be assessed by combining patency rates and clinical outcome according to standardized categories.

A new animal model to study intimal hyperplasia in arteriovenous fistulas.

BACKGROUND: Intimal hyperplasia (IH) plays a key role in the failure of arteriovenous (AV) fistulas. The animal models available to study IH in AV fistulas are expensive and do not mimic the development of truly stenotic IH. In this study we examined whether goats are a more suitable model to study IH in AV fistulas. MATERIALS AND METHODS: Thirteen direct and four bridge graft AV fistulas between the carotid artery and the jugular vein of goats were explanted 10 to 195 days after creation. Immunohistochemical staining and morphometric measurements of intima and media were performed in the artery, the vein, the toe, and the heel of the venous anastomosis. Ratios of intimal to medial thickness (Ith/Mth) and area (Ia/Ma) were calculated. RESULTS: IH developed in all goats, mainly at the anastomosis (Ia/Ma = 0.17) and the efferent vein (Ia/Ma = 0.31). The artery was almost free of lesions (Ia/Ma = 0.03). In the efferent vein, Ith/Mth varied between 0.59 and 0.68. In the anastomosis the largest value of Ith/Mth was measured at the suture lines (0.88 and 0.91). Absolute intimal area increased with time. IH contained many vascular smooth muscle cells with a patchy display of desmin positivity, an abundance of smooth muscle cell alpha-actin positivity, and almost complete endothelial cell coverage. Occlusion was due to thrombus formation on the IH. CONCLUSION: A clear intimal hyperplasia developed in AV fistulas in goats at locations comparable to those in humans. Therefore, the AV fistula model in the goat may be seen as an effective model to study IH in hemodialysis AV fistulas.

Haemodialysis vascular access and fistula surveillance methods in The Netherlands.

INTRODUCTION: As the mean age of haemodialysis patients is increasing, fewer patients will have suitable blood vessels for the creation of a Brescia-Cimino fistula and an increased use of graft implants is to be expected. METHODS: To assess the change in vascular access and the use of surveillance techniques, all haemodialysis centres in The Netherlands received a questionnaire regarding the types of vascular accesses and surveillance techniques used in their department on 31 December, 1996. The results were related to a comparable study done in 1987, shown between brackets. RESULTS: The response of the haemodialysis staff was 96%, of the vascular surgeons this was 91%. Sixty-two per cent (70%) of the patients had Brescia-Cimino fistulas, 21% (13%) Polytetrafluoroethylene (PTFE) graft fistulas, 17% (17%) other vascular accesses. Scheduled surveillance for stenosis detection was done by recirculation measurements in 6%, venous pressure measurements in 31%, Duplex scanning in 11% and angiography in 11% of the centres. When access problems occurred, 79% of the physicians performed recirculation measurements, 38% venous pressure measurements, 79% Duplex scanning and 100% angiography. In 46% of the centres PTA was done occasionally, and in 46% routinely for the treatment of stenotic complications in arteriovenous fistulas. CONCLUSIONS: The use of PTFE grafts and other types of vascular accesses has increased at the expense of BC fistulas. Recirculation and venous pressure measurements are primarily done when problems occur and not according to a standard surveillance schedule. For visualization of failing fistulas, 79% of the centres uses Duplex ultrasound analysis and 100% angiography. The popularity of PTA has increased from 46 to 92% of the centres.

Effects of a venous cuff at the venous anastomosis of polytetrafluoroethylene grafts for hemodialysis vascular access.

INTRODUCTION AND METHODS: The most frequent complication of polytetrafluoroethylene (PTFE) arteriovenous grafts for hemodialysis is thrombotic occlusion due to stenosis caused by intimal hyperplasia. This complication is also known for peripheral bypass grafts. Because the use of a venous cuff at the distal anastomosis improves the patency of peripheral bypass grafts, we considered that it might also improve the patency of PTFE arteriovenous grafts. Therefore, a randomized multicenter trial was carried out to study the effect of a venous cuff at the venous anastomosis of PTFE arteriovenous grafts on the development of stenoses and the patency rates. RESULTS: Of the 120 included patients, 59 were randomized for a venous cuff. The incidence of thrombotic occlusion was lower in the cuff group (0.68 per patient-year) than in the no-cuff group (0. 88 per patient-year; P =.0007). However, the primary and secondary patency rates were comparable. The cuff group tended to have fewer stenoses at the venous and arterial anastomoses when examined with duplex scan. Graft failure was higher in patients with an initial anastomosing vein diameter smaller than 4 mm (7 of 18 [39%]) than in those with a vein diameter of 4 mm or larger (16 of 88 [18%]; P =. 052). Local edema, skin atrophy, and obesity yielded a higher risk on graft failure (23% vs 11%). CONCLUSION: A venous cuff at the venous anastomosis of PTFE arteriovenous grafts for hemodialysis reduced the incidence of thrombotic occlusions; stenosis at the venous anastomosis was reduced. However, this did not result in a better patency rate. Therefore, the venous cuff should not be used routinely. Initial vein diameter and local problems (edema, obesity, or skin atrophy) appear to be the most important risk factors for graft failure.